2 August 2021 - Novartis Korea said Monday its interleukin-17a inhibitor Cosentyx (secukinumab) began receiving reimbursement as a first-line biologics for progressive psoriatic arthritis patients who had an inadequate response to existing disease-modifying anti-rheumatic drugs.

With the recent reimbursement, the government provides another therapeutic option for domestic psoriatic arthritis patients with health insurance coverage for the first-line biological treatment in improving joint and skin symptoms.

Read Korea Biomedical Review article